| Megan Ashley Altwine, PHARMD | |
|
1800 Syracuse Ave, Norfolk, NE 68701-2458 | |
| (402) 371-8834 | |
| Not Available |
| Full Name | Megan Ashley Altwine |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1800 Syracuse Ave, Norfolk, Nebraska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144564667 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 13177 (Nebraska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Megan Ashley Altwine, PHARMD 1800 Syracuse Ave, Norfolk, NE 68701-2458 Ph: (402) 371-8834 | Megan Ashley Altwine, PHARMD 1800 Syracuse Ave, Norfolk, NE 68701-2458 Ph: (402) 371-8834 |
News Archive
The world's most widespread test for ovarian cancer reports false-positives in 94 of 100 diagnosed cases. Now, chemists at the University of Copenhagen working with clinical researchers at University College London have developed a method able to halve the number of false-positives.
A new report from Oxfam and 62 other non-governmental organizations and health groups finds that international goals aiming to reduce child and maternal mortality rates are "desperately off track," with four million babies around the world dying annually within 28 days of birth, Agence France-Press reports (9/13).
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
By looking at National Health Interview Survey data of more than 230,000 patients from 1999-2009, researchers were able to compare Medicaid with privately insured patients. More than 39 percent of those enrolled in Medicaid in the sample used the ER versus 17.7 percent of privately insured patients. Medicaid patients wer much more likely to have "specific barriers to timely primary care."
› Verified 8 days ago
Anton Anderson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1301 W Norfolk Ave, Norfolk, NE 68701 Phone: 402-371-9438 | |
Dr. Patrick M Hammond, RP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1001 W Benjamin Ave, Norfolk, NE 68701 Phone: 402-379-8728 | |
Mrs. Greta Ann Hogrefe, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 120 E Norfolk Ave, Norfolk, NE 68701 Phone: 402-371-0610 Fax: 402-844-3157 | |
Dr. Kari Charm Hamer, R.P. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2700 W Norfolk Ave, Norfolk, NE 68701 Phone: 402-644-7523 Fax: 402-644-7267 | |
Mark A Boeding, R.P. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2700 W Norfolk Ave, Norfolk, NE 68701 Phone: 402-371-4880 Fax: 402-644-7267 | |
Mary Hammond, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1001 W Benjamin Ave, Norfolk, NE 68701 Phone: 402-379-8728 |